Experts from a wide range of fields are working tirelessly to combat the COVID-19 pandemic, and these variant strains of SARS-CoV-2, with vaccines and therapeutics. At GSK, we are committed to developing solutions that can fight the virus both now and into the future.
What are we doing to develop COVID-19 solutions?
Our response to COVID-19 has been one of the broadest in the industry, with potential treatments in development in addition to our vaccine candidates.
With a proven track record in antivirals – from developing the first medicine for the treatment of HIV and AIDS through to numerous different vaccines for viral diseases – we believe that GSK has the history and ability to look for a range of solutions to COVID-19 from prevention to treatment.
Collaborating with other leading healthcare companies and research institutions around the world to develop and deliver solutions for the pandemic is central to our approach.
We have several collaborations to develop COVID-19 vaccines where we are contributing our pandemic adjuvant technology – these have led to three vaccine candidates that are now progressing through clinical testing. As new SARS-CoV-2 variants emerge around the globe, a key priority is to understand how they might impact existing vaccines and those in development. Together with our collaborators, we are exploring strategies that could help address variants. This could include studying vaccine candidates in countries where high levels of variants are spreading, adapting them to increase their level of protection against multiple variants, or potentially developing new vaccines.
In addition to our collaborations to develop adjuvanted protein-based COVID-19 vaccines, we are also working in partnership with CureVac on the development of next-generation mRNA vaccines for COVID-19 that could have the potential to address multiple emerging variants. The aim of this work is to offer broader protection against a variety of different SARS-CoV2 variants and to enable a quick response to new variants that could emerge in the future.
While the development of vaccines has been very successful, it takes time to roll them out and people around the world continue to be infected by and hospitalised due to COVID-19. Also, vaccination will not reach 100% of the world’s population. This is why it’s also important that we continue to pursue diverse therapeutic options to help prevent and treat disease.
In addition to re-purposing and studying investigational medicines that were already in our GSK pipeline, we announced a collaboration with clinical-stage immunology company Vir Biotechnology in April 2020 to develop existing and identify new anti-viral antibodies that could potentially be used as therapeutic or preventive options for COVID-19.
Our COVID-19 therapeutics are currently being tested in a broad range of patients at different stages from prevention to treatment.